E
Elisabetta Tabolacci
Researcher at Catholic University of the Sacred Heart
Publications - 45
Citations - 1638
Elisabetta Tabolacci is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Fragile X syndrome & DNA methylation. The author has an hindex of 20, co-authored 38 publications receiving 1489 citations. Previous affiliations of Elisabetta Tabolacci include The Catholic University of America.
Papers
More filters
Journal ArticleDOI
A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability
Francesca Zalfa,Boris Eleuteri,Kirsten S. Dickson,Valentina Mercaldo,Silvia De Rubeis,Alessandra di Penta,Elisabetta Tabolacci,Pietro Chiurazzi,Giovanni Neri,Seth G. N. Grant,Seth G. N. Grant,Claudia Bagni +11 more
TL;DR: In mice, it is found that FMRP binds, in vivo, the mRNA encoding PSD-95, a key molecule that regulates neuronal synaptic signaling and learning, and evidence that dysregulation of mRNA stability may contribute to the cognitive impairments in individuals with FXS is provided.
Journal ArticleDOI
Molecular dissection of the events leading to inactivation of the FMR1 gene
Roberta Pietrobono,Elisabetta Tabolacci,Francesca Zalfa,Ilaria Zito,Alessandra Terracciano,Umberto Moscato,Claudia Bagni,Ben A. Oostra,Pietro Chiurazzi,Giovanni Neri +9 more
TL;DR: In this article, a lymphoblastoid cell line (5106) derived from a rare individual of normal intelligence with an unmethylated full mutation of the FMR1 gene, allowed them to reconstruct the chain of molecular events leading to the inactivation and to fragile X syndrome.
Journal ArticleDOI
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5‐azadeoxycytidine
Roberta Pietrobono,Maria Grazia Pomponi,Elisabetta Tabolacci,Ben A. Oostra,Pietro Chiurazzi,Giovanni Neri +5 more
TL;DR: This work shows that treatment with 5-azadeoxycytidine of fragile X cell lines results in passive demethylation of the FMR1 gene promoter, and investigates the extent of methylation in the full mutation (CGG repeat) itself by Southern blot analysis after digestion with methylation-sensitive enzymes Fnu4HI and McrBC.
Journal ArticleDOI
A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys.
M. Giulia Torrioli,Silvia Vernacotola,Laura Peruzzi,Elisabetta Tabolacci,Montserrat Milà,Roberto Militerni,Sebastiano Musumeci,Feliciano J. Ramos,María Frontera,Giovanni Sorge,Elisabetta Marzullo,Giusi Romeo,Louis Vallee,Edvige Veneselli,Elena Cocchi,Eleonora Garbarino,Umberto Moscato,Pietro Chiurazzi,Stefania D'Iddio,Menotti Calvani,Giovanni Neri +20 more
TL;DR: In this article, L-acetylcarnitine (LAC) was shown to reduce hyperactivity in fragile X syndrome (FXS) children with methylphenidate (MPH) treatment.
Journal ArticleDOI
Epigenetic analysis reveals a euchromatic configuration in the FMR1 unmethylated full mutations.
Elisabetta Tabolacci,Umberto Moscato,Francesca Zalfa,Claudia Bagni,Claudia Bagni,Pietro Chiurazzi,Giovanni Neri +6 more
TL;DR: Epigenetic analysis of the FMR1 gene demonstrated the lack of DNA methylation and a methylation pattern of lysines 4 and 27 on histone H3 similar to that of normal controls, in accordance with normal transcription levels and consistent with a euchromatic configuration.